Can the Reduction of Iron Availability Caused by Tea Consumption Change the Gut Microbiota Composition and Disrupt Host Body-iron Status

NCT ID: NCT05019573

Last Updated: 2021-08-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-20

Study Completion Date

2022-01-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Iron is an essential micronutrient for nearly all living organisms, including microbes. The adult human body contains approximately 3-5 g of iron (45-55 mg/kg of body weight in adult women and men, respectively). Iron-deficiency related anaemia (IDA) is a major public health problem that affects more than 2 billion people globally and this represents 24.8% of the world's population. According to World Health Organisation (WHO), iron deficiency is the most common cause of anaemia worldwide, with infants, children and women at higher risk, making it a global public health problem. Much iron deficiency is a result of poor iron dietary absorption since iron is poorly absorbed (\~15%). Absorption inhibition factors (iron chelators) like phytate and tannins, found in tea and vegetables have been reported to act as potent iron uptake inhibitors. Despite its health benefits, tea-containing polyphenols (tannins) have been associated with reduction and disruption of iron absorption, acting as inhibitors of non-haem iron uptake, potentially resulting in poor iron status. However, most studies on the effect of tea on iron absorption are largely based on isotope-labelled single meal studies and animal studies. Iron is a requirement of many microorganisms, as such changes in iron availability can also have an impact on the gut microbiota. Long-term controlled human intervention studies to investigate the effect of tea on iron absorption and the effect on gut microbiota composition are scarce. In addition, the impact of dietary tannins on the gut microbiota is not understood. Thus, this proposed human intervention trial will investigate the combined effect of tea-tannins on iron status, inflammation and gut microbiota composition. This will be the first study to consider this combination of factors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Focus of Study: 1- Effect of Tea Consumption on Gut Microbiota Focus of Study: 2- Effect of Tea Consumption on Body-iron Status

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

A randomised, double-blind (subject/investigator), placebo controlled, parallel study.
Primary Study Purpose

SCREENING

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Black tea group

Volunteers meeting inclusion/exclusion criteria will be given an appropriate number of black tea samples twice a day with main meals for the 4 weeks of the treatment.

Group Type EXPERIMENTAL

Black tea

Intervention Type DIETARY_SUPPLEMENT

Black tea twice a day for 4 weeks

Placebo group

Volunteers meeting inclusion/exclusion criteria will be given an appropriate number of placebo tea samples twice a day with main meals for the 4 weeks of the treatment.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Placebo tea twice a day for 4 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Black tea

Black tea twice a day for 4 weeks

Intervention Type DIETARY_SUPPLEMENT

Placebo

Placebo tea twice a day for 4 weeks

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: 18-60 years
* Gender: Male or Female
* Volunteers agree to sign an informal written consent form
* General good health
* Normal haemoglobin and serum ferritin levels

Exclusion Criteria

* Regular tea drinkers
* Use of antibiotics, prebiotics or probiotics (in food products or as supplements), laxatives, anti-spasmodic, anti-diarrhoea drugs, (e.g. Orlistat, Lactulose) in the last 4 weeks prior to, or during the study period.
* Use of any iron supplement in the last 6 months prior to the study period.
* If participants have received bowel preparation for investigative procedures in the 4 weeks prior to the study.
* Surgical resection of any part of the bowel.
* If you have any chronic gut disorder/disease, such as IBS, IBD, etc. or other conditions that might affect the gut environment, e.g. coeliac disease. If participants are taking any medication that could affect the iron absorption (e.g. lansoprazole, omeprazole). Those with gluten allergies (e.g. Celiac disease) must be excluded as the placebo may contain gluten
* If participants are pregnant or are lactating.
* If participants have a BMI \> 30 kg/m2.
* Severe allergy or any history of severe abnormal drug reaction, drug or alcohol abuse
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Unilever R&D

INDUSTRY

Sponsor Role collaborator

University of Reading

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gemma Walton

Principle Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Reading

Reading, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Amro Duhduh

Role: primary

07950285776

Andrea Monteagudo

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UREC 20/04

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.